Authorized purpose: Concurrent or secondary CAD assistance to interpreting physicians for detection, localization, and characterization of soft-tissue densities (masses, architectural distortions, and asymmetries) and calcifications; not a primary read.
Clinical role
Concurrent or secondary CAD read that informs, but does not replace, the interpreting physician's primary diagnostic and patient-management decisions.
Images and patients
Mammography/DBT · Breast, including soft-tissue densities and calcifications in 3D DBT slices.
Key limitation
Keep in mind: The output is a concurrent or secondary read and does not replace clinical expertise or primary diagnostic and patient-management decisions. Certainty of Finding and Case Scores are based on a 50% cancer prevalence population, are not calibrated to the intended-use or pivotal-study prevalence, and represent relative suspicion rather than an absolute clinical probability of malignancy. Use is limited to the listed compatible DBT systems.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent or secondary CAD assistance to interpreting physicians for detection, localization, and characterization of soft-tissue densities (masses, architectural distortions, and asymmetries) and calcifications; not a primary read.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast, including soft-tissue densities and calcifications in 3D DBT slices. Input: 3D DBT exams from compatible systems: Hologic Selenia Dimensions or 3Dimensions, GE Senographe Essential with SenoClaire, GE Senographe Pristina, Siemens Inspiration, and Siemens Revelation, with the stated Siemens standard or Empire reconstructions where applicable.
Who uses it?Intended users: Interpreting physicians.
What does the software produce?Output: Detected regions marked or contoured on DBT slices, with a Certainty of Finding score for each detected region and a Case Score for each study, each represented on a 0%-100% scale; scores and marks assist the physician in identifying findings for confirmation or dismissal.
What is its most important limitation?Key limitation: The output is a concurrent or secondary read and does not replace clinical expertise or primary diagnostic and patient-management decisions. Certainty of Finding and Case Scores are based on a 50% cancer prevalence population, are not calibrated to the intended-use or pivotal-study prevalence, and represent relative suspicion rather than an absolute clinical probability of malignancy. Use is limited to the listed compatible DBT systems.
Clinical takeaway. Clinical role: Concurrent or secondary CAD assistance to interpreting physicians for detection, localization, and characterization of soft-tissue densities (masses, architectural distortions, and asymmetries) and calcifications; not a primary read.
Evidence takeaway. Evidence from the reviewed source record: Verification included unit, integration, and regression testing. Hologic and GE supplemental standalone studies compared ProFound AI V3.0 with the prior version using case sensitivity, false-positive rate per 3D volume, and AUC, with non-inferiority conclusions for the described screening populations; paired comparisons reported increased specificity from V2.0 to V3.0. The packet text provides no numeric subject-device sensitivity, specificity, AUC, PPV, NPV, or reader-delta values.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent or secondary CAD assistance to interpreting physicians for detection, localization, and characterization of soft-tissue densities (masses, architectural distortions, and asymmetries) and calcifications; not a primary read.
3D DBT exams from compatible systems: Hologic Selenia Dimensions or 3Dimensions, GE Senographe Essential with SenoClaire, GE Senographe Pristina, Siemens Inspiration, and Siemens Revelation, with the stated Siemens standard or Empire reconstructions where applicable.
Detected regions marked or contoured on DBT slices, with a Certainty of Finding score for each detected region and a Case Score for each study, each represented on a 0%-100% scale; scores and marks assist the physician in identifying findings for confirmation or dismissal.
The output is a concurrent or secondary read and does not replace clinical expertise or primary diagnostic and patient-management decisions. Certainty of Finding and Case Scores are based on a 50% cancer prevalence population, are not calibrated to the intended-use or pivotal-study prevalence, and represent relative suspicion rather than an absolute clinical probability of malignancy. Use is limited to the listed compatible DBT systems.
Verification included unit, integration, and regression testing. Hologic and GE supplemental standalone studies compared ProFound AI V3.0 with the prior version using case sensitivity, false-positive rate per 3D volume, and AUC, with non-inferiority conclusions for the described screening populations; paired comparisons reported increased specificity from V2.0 to V3.0. The packet text provides no numeric subject-device sensitivity, specificity, AUC, PPV, NPV, or reader-delta values.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Verification included unit, integration, and regression testing. Hologic and GE supplemental standalone studies compared ProFound AI V3.0 with the prior version using case sensitivity, false-positive rate per 3D volume, and AUC, with non-inferiority conclusions for the described screening populations; paired comparisons reported increased specificity from V2.0 to V3.0. The packet text provides no numeric subject-device sensitivity, specificity, AUC, PPV, NPV, or reader-delta values.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
ProFound AI® Software V3.0 regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K203822
Samplen=694
IndependenceIndependence not established
K203822
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203822. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: 3D DBT exams from compatible systems: Hologic Selenia Dimensions or 3Dimensions, GE Senographe Essential with SenoClaire, GE Senographe Pristina, Siemens Inspiration, and Siemens Revelation, with the stated Siemens standard or Empire reconstructions where applicable.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Verification and validation included deployment on a DICOM platform successfully tested for clinical network integration, with output displayed through the compatible DBT and softcopy-workstation workflow described in the packet. Specific local PACS, RIS, or interface compatibility is not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes ProFound AI V3.0 as deployed on a standalone computer and on a DICOM platform tested for clinical network integration, with a softcopy workstation as the output device. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Output Device Softcopy Workstation Softcopy Workstation Deployment Standalone computer Standalone computer" … "ProFound AI V3.0 is deployed on a DICOM platform that has been successfully tested for clinical network integration.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Detected regions marked or contoured on DBT slices, with a Certainty of Finding score for each detected region and a Case Score for each study, each represented on a 0%-100% scale; scores and marks assist the physician in identifying findings for confirmation or dismissal.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Detected regions marked or contoured on DBT slices, with a Certainty of Finding score for each detected region and a Case Score for each study, each represented on a 0%-100% scale; scores and marks assist the physician in identifying findings for confirmation or dismissal.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes ProFound AI V3.0 as deployed on a standalone computer and on a DICOM platform tested for clinical network integration, with a softcopy workstation as the output device. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Output Device Softcopy Workstation Softcopy Workstation Deployment Standalone computer Standalone computer" … "ProFound AI V3.0 is deployed on a DICOM platform that has been successfully tested for clinical network integration.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Verification and validation included deployment on a DICOM platform successfully tested for clinical network integration, with output displayed through the compatible DBT and softcopy-workstation workflow described in the packet. Specific local PACS, RIS, or interface compatibility is not established.
iCAD's coordinated vulnerability disclosure statement commits to vulnerability intake via support@icadmed.com, confidential report handling, an evaluation response with an expected resolution date based on severity, progress updates to the reporter, and a safe-harbor commitment not to take legal action against reporters who follow the policy.
Vendor-wide
Checked 2026-10-27
Vendor statement on the iCAD owning domain (icadmed.com); the page banner notes iCAD is now part of DeepHealth, but the statement is iCAD's own product/system disclosure policy. No certification or audit report was read; exact-release scope is not established.
iCAD's coordinated vulnerability disclosure statement states confidential intake, an evaluation response with a severity-based expected resolution date, and progress updates to the reporter.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The statement names iCAD generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for ProFound AI Software V3.0; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K203822 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.